Effects of Esketamine on Postoperative Hospital Anxiety and Depression Scale Scores in Patients Undergoing Laparoscopic Radical Resection for Colorectal Cancer.
J Invest SurgSep 11, 2026 (epub)
Lindai He, Zhihua Sun, Qulian Guo et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial examined the impact of intravenous esketamine on postoperative anxiety and depression in patients undergoing laparoscopic radical resection for colorectal cancer. The study found that esketamine significantly reduced Hospital Anxiety and Depression Scale (HADS) scores on postoperative days 1 and 3 compared to a control group, indicating improved emotional outcomes.
Key findings
- Esketamine group had significantly lower HADS-A scores on postoperative day 1 and 3 compared to control.
- HADS-D scores were also significantly lower in the esketamine group on postoperative days 1 and 3.
- The esketamine group showed reduced 24-hour interleukin-6 levels compared to the control group.
- Patient satisfaction was higher in the esketamine group compared to the control group.
Why it matters
The findings suggest that esketamine may be an effective adjunct in managing postoperative anxiety and depression, potentially leading to better overall patient outcomes and satisfaction after major surgery.